Skip to content
Open access

Discovery of novel 1,3,4-thiadiazole derivatives as potential dual EGFR/VEGFR inhibitors with activity against breast, colon, and liver cancer cells: biological evaluation and molecular docking investigation

Nov 2026 · RSC Advances · 0 citations
Medicine

Abstract

New derivatives of the 1,3,4-thiadiazole scaffold were synthesized and evaluated for their cytotoxic effects on breast (MCF-7), hepatic (HepG-2), and colorectal (HCT-116) carcinomas. The most active compounds (7, 8, 15, and 16) exhibited substantial, broad-spectrum anticancer efficacy, with IC50 values ranging from 1.58–4.27 µM relative to doxorubicin. To explore their potential modulatory capacity on receptor tyrosine kinases (RTKs), compounds 7, 8, 15, and 16 were evaluated for enzymatic efficacy against VEGFR-2, and the most active hits, 7 and 15, were further assessed against EGFR. The findings suggest a possible VEGFR/EGFR-mediated inhibition of cancer cell proliferation, with compounds 7 and 15 showing enzymatic inhibitory activity, displaying IC50 values of 0.42 and 0.23 µM for EGFR and 0.17 and 0.16 µM for VEGFR-2, respectively. Furthermore, both new hits demonstrated reduced cytotoxicity towards normal WI-38 cells, signifying favorable safety profiles. Molecular docking investigations of the active compounds within the VEGFR-2 and EGFR ATP-binding sites supported these in vitro assay results. Overall, these findings point to a potential anticancer activity and dual EGFR/VEGFR inhibitors for these compounds.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.